These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 21763412)

  • 1. Phaleria macrocarpa (Scheff.) Boerl fruit aqueous extract enhances LDL receptor and PCSK9 expression in vivo and in vitro.
    Chong SC; Dollah MA; Chong PP; Maha A
    J Ethnopharmacol; 2011 Sep; 137(1):817-27. PubMed ID: 21763412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phaleria macrocarpa Boerl. (Thymelaeaceae) leaves increase SR-BI expression and reduce cholesterol levels in rats fed a high cholesterol diet.
    Andriani Y; Tengku-Muhammad TS; Mohamad H; Saidin J; Syamsumir DF; Chew GS; Abdul Wahid ME
    Molecules; 2015 Mar; 20(3):4410-29. PubMed ID: 25759957
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of PCSK9 as a novel strategy for the treatment of hypercholesterolemia.
    Lopez D
    Drug News Perspect; 2008; 21(6):323-30. PubMed ID: 18836590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Curcumin enhances cell-surface LDLR level and promotes LDL uptake through downregulation of PCSK9 gene expression in HepG2 cells.
    Tai MH; Chen PK; Chen PY; Wu MJ; Ho CT; Yen JH
    Mol Nutr Food Res; 2014 Nov; 58(11):2133-45. PubMed ID: 25164566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Proprotein convertase substilisin/kexin type 9 antagonism reduces low-density lipoprotein cholesterol in statin-treated hypercholesterolemic nonhuman primates.
    Liang H; Chaparro-Riggers J; Strop P; Geng T; Sutton JE; Tsai D; Bai L; Abdiche Y; Dilley J; Yu J; Wu S; Chin SM; Lee NA; Rossi A; Lin JC; Rajpal A; Pons J; Shelton DL
    J Pharmacol Exp Ther; 2012 Feb; 340(2):228-36. PubMed ID: 22019884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting PCSK9 for the treatment of hypercholesterolemia.
    Hedrick JA
    Curr Opin Investig Drugs; 2009 Sep; 10(9):938-46. PubMed ID: 19705336
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes.
    Sahebkar A; Watts GF
    Clin Ther; 2013 Aug; 35(8):1082-98. PubMed ID: 23932550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Piceatannol reduces resistance to statins in hypercholesterolemia by reducing PCSK9 expression through p300 acetyltransferase inhibition.
    Kim HJ; Lee J; Chung MY; Hong S; Park JH; Lee SH; Park SW; Choi HK; Hwang JT
    Pharmacol Res; 2020 Nov; 161():105205. PubMed ID: 32998069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypocholesterolemic effect of stilbenes containing extract-fraction from Cajanus cajan L. on diet-induced hypercholesterolemia in mice.
    Luo QF; Sun L; Si JY; Chen DH
    Phytomedicine; 2008 Nov; 15(11):932-9. PubMed ID: 18420398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New CETP inhibitor K-312 reduces PCSK9 expression: a potential effect on LDL cholesterol metabolism.
    Miyosawa K; Watanabe Y; Murakami K; Murakami T; Shibata H; Iwashita M; Yamazaki H; Yamazaki K; Ohgiya T; Shibuya K; Mizuno K; Tanabe S; Singh SA; Aikawa M
    Am J Physiol Endocrinol Metab; 2015 Jul; 309(2):E177-90. PubMed ID: 26015437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of AMG 145 on low-density lipoprotein cholesterol levels: results from 2 randomized, double-blind, placebo-controlled, ascending-dose phase 1 studies in healthy volunteers and hypercholesterolemic subjects on statins.
    Dias CS; Shaywitz AJ; Wasserman SM; Smith BP; Gao B; Stolman DS; Crispino CP; Smirnakis KV; Emery MG; Colbert A; Gibbs JP; Retter MW; Cooke BP; Uy ST; Matson M; Stein EA
    J Am Coll Cardiol; 2012 Nov; 60(19):1888-98. PubMed ID: 23083772
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypocholesterolemic effect of daily fisetin supplementation in high fat fed Sprague-Dawley rats.
    Shin MJ; Cho Y; Moon J; Jeon HJ; Lee SM; Chung JH
    Food Chem Toxicol; 2013 Jul; 57():84-90. PubMed ID: 23524313
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Statins and ezetimibe modulate plasma proprotein convertase subtilisin kexin-9 (PCSK9) levels.
    Davignon J; Dubuc G
    Trans Am Clin Climatol Assoc; 2009; 120():163-73. PubMed ID: 19768174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Hypocholesterolemic effect of stilbene extract from Cajanus cajan L. on serum and hepatic lipid in diet-induced hyperlipidemic mice].
    Luo QF; Sun L; Si JY; Chen DH; Du GH
    Yao Xue Xue Bao; 2008 Feb; 43(2):145-9. PubMed ID: 18507340
    [TBL] [Abstract][Full Text] [Related]  

  • 15. LDL receptor and Pcsk9 transcripts are decreased in liver of ovariectomized rats: effects of exercise training.
    Ngo Sock ET; Chapados NA; Lavoie JM
    Horm Metab Res; 2014 Jul; 46(8):550-5. PubMed ID: 24619822
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Suppression of Idol expression is an additional mechanism underlying statin-induced up-regulation of hepatic LDL receptor expression.
    Dong B; Wu M; Cao A; Li H; Liu J
    Int J Mol Med; 2011 Jan; 27(1):103-10. PubMed ID: 21069265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MG132, a proteasome inhibitor, enhances LDL uptake in HepG2 cells in vitro by regulating LDLR and PCSK9 expression.
    Yan H; Ma YL; Gui YZ; Wang SM; Wang XB; Gao F; Wang YP
    Acta Pharmacol Sin; 2014 Aug; 35(8):994-1004. PubMed ID: 25042549
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased plasma cholesterol and hypersensitivity to statins in mice lacking Pcsk9.
    Rashid S; Curtis DE; Garuti R; Anderson NN; Bashmakov Y; Ho YK; Hammer RE; Moon YA; Horton JD
    Proc Natl Acad Sci U S A; 2005 Apr; 102(15):5374-9. PubMed ID: 15805190
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LDL-R promoting activity of peptides derived from human PCSK9 catalytic domain (153-421): design, synthesis and biochemical evaluation.
    Alghamdi RH; O'Reilly P; Lu C; Gomes J; Lagace TA; Basak A
    Eur J Med Chem; 2015 Mar; 92():890-907. PubMed ID: 25679794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Berberine decreases PCSK9 expression in HepG2 cells.
    Cameron J; Ranheim T; Kulseth MA; Leren TP; Berge KE
    Atherosclerosis; 2008 Dec; 201(2):266-73. PubMed ID: 18355829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.